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OBJECTIVE—Depletion of body fat stores during uncontrolled,
insulin-deﬁcient diabetes (uDM) results in markedly reduced
plasma leptin levels. This study investigated the role of leptin
deﬁciency in the genesis of severe insulin resistance and related
metabolic and neuroendocrine derangements induced by uDM.
RESEARCH DESIGN AND METHODS—Adult male Wistar
rats remained nondiabetic or were injected with the -cell toxin,
streptozotocin (STZ) to induce uDM and subsequently under-
went subcutaneous implantation of an osmotic minipump con-
taining either vehicle or leptin at a dose (150 g/kg/day) designed
to replace leptin at nondiabetic plasma levels. To control for
leptin effects on food intake, another group of STZ-injected
animals were pair fed to the intake of those receiving leptin.
Food intake, body weight, and blood glucose levels were mea-
sured daily, with body composition and indirect calorimetry
performed on day 11, and an insulin tolerance test to measure
insulin sensitivity performed on day 16. Plasma hormone and
substrate levels, hepatic gluconeogenic gene expression, and mea-
sures of tissue insulin signal transduction were also measured.
RESULTS—Physiologic leptin replacement prevented insulin
resistance in uDM via a mechanism unrelated to changes in food
intake or body weight. This effect was associated with reduced
total body fat and hepatic triglyceride content, preservation of
lean mass, and improved insulin signal transduction via the
insulin receptor substrate–phosphatidylinositol-3-hydroxy kinase
pathway in the liver, but not in skeletal muscle or adipose tissue.
Although physiologic leptin replacement lowered blood glucose
levels only slightly, it fully normalized elevated plasma glucagon
and corticosterone levels and reversed the increased hepatic
expression of gluconeogenic enzymes characteristic of rats with
uDM.
CONCLUSIONS—We conclude that leptin deﬁciency plays a
key role in the pathogenesis of severe insulin resistance and
related endocrine disorders in uDM. Treatment of diabetes in
humans may beneﬁt from correction of leptin deﬁciency as well
as insulin deﬁciency. Diabetes 59:1626–1634, 2010
R
ecent evidence implicates leptin not only in the
regulation of energy balance but also in glucose
homeostasis as well. In addition to hyperphagia
and obesity, insulin resistance is a prominent
feature of animal models characterized by reduced leptin
signaling (1), and leptin administration improves insulin
sensitivity and glucose metabolism in these models (2,3)
independently of its effects on energy homeostasis (4).
Investigation into the role of leptin in glucose metabolism
has focused largely on genetic models of impaired leptin
signaling (e.g., leptin-deﬁcient ob/ob mice), whereas other
studies have used pharmacologic doses of leptin (1–6). In
this study we investigated the physiologic role of leptin in
glucose metabolism by determining the contribution made
by leptin deﬁciency to the severe insulin resistance and
associated metabolic and endocrine dysfunction charac-
teristic of uncontrolled, insulin-deﬁcient diabetes (uDM).
Severe leptin deﬁciency is a well-documented conse-
quence of uDM that occurs after destruction of insulin-
secreting -cells (7,8). Because insulin is required for the
synthesis and storage of triglyceride in adipose tissue,
weight gain cannot occur in uDM, and the associated loss
of body fat is accompanied by markedly reduced plasma
leptin levels. This effect, in turn, is implicated in the
mechanism whereby uDM increases food intake (9), be-
cause exogenous leptin administration at doses that pre-
vent a fall in plasma leptin levels also prevent hyperphagia
in uDM (8). Another feature of uDM in humans is progres-
sive, severe insulin resistance (10–12), an effect also
observed in streptozotocin (STZ)-induced diabetes in rats
(13). Although insulin deﬁciency clearly underlies hyper-
glycemia and weight loss in uDM, the contribution of
markedly reduced plasma leptin levels to insulin resis-
tance and related metabolic and endocrine derangements
in this setting remains to be determined. Because plasma
levels of leptin as well as of insulin are normalized by
insulin treatment of STZ-induced diabetes, at least some of
the beneﬁcial effects that have been ascribed to insulin
treatment could result from restoring leptin action to
normal (7). Indeed, hyperleptinemia generated either by
pharmacologic administration of leptin (5) or with adeno-
viral gene therapy (14) ameliorates hyperglycemia and
associated increases of plasma glucagon levels in STZ-
induced diabetes, despite persistently low insulin levels.
These data raise the possibility that deﬁcient endogenous
leptin signaling may underlie at least some manifestations
of uDM.
Based on these considerations, we sought to determine
the extent to which deﬁciency of endogenous leptin con-
tributes to insulin resistance and related endocrine dys-
function in STZ-induced diabetes. To accomplish this goal,
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dose that prevents leptin deﬁciency in rats with STZ-
induced uDM. We found that physiologic leptin replace-
ment prevented the development of insulin resistance in
uDM via a mechanism independent of its effects on food
intake and body weight. Moreover, this leptin effect was
associated with normalization of elevated plasma levels of
glucagon and corticosterone, with the reversal of in-
creased hepatic expression of the gluconeogenic genes,
glucose-6-phosphatase (G6Pase), and phosphoenolpyru-
vate kinase (Pepck), and with improved insulin signal
transduction via the insulin receptor substrate–phosphati-
dylinositol-3-hydroxy kinase (IRS-PI3K) pathway in the
liver, but not in skeletal muscle or adipose tissue. In
comparison, physiologic leptin replacement only modestly
reduced hyperglycemia in STZ-induced diabetic rats and
did not alter the potent upregulation of hepatic Igfbp2
mRNA levels previously reported (15). Taken together,
these data suggest that reduced leptin levels contribute to
the progressive, severe insulin resistance characteristic of
uDM via a mechanism that appears to predominantly
involve the liver.
RESEARCH DESIGN AND METHODS
Adult male Wistar rats (Harlan, Indianapolis, IN) were housed in individual
cages under speciﬁc pathogen–free conditions, maintained in a temperature-
controlled room with a 12:12-h light/dark cycle and provided with ad libitum
access to water and standard laboratory chow (PMI Nutrition International)
unless otherwise stated. All procedures were performed in accordance with
the National Institutes of Health Guidelines for the Care and Use of Labora-
tory Animals and were approved by the Animal Care Committee at the
University of Washington.
Effect of physiologic leptin replacement during STZ-induced leptin
deﬁciency. To induce uDM, rats received two consecutive daily subcutane-
ous injections (40 mg/kg) of freshly prepared STZ (Sigma) dissolved in
ice-cold sodium citrate (pH 4.5). Subsequently, under isoﬂurane anesthesia,
two groups of diabetic animals (n  7–9 per group) received a subcutaneously
implanted osmotic minipump (Alzet model 2ML4; DURECT) containing either
vehicle (STZ-veh) or leptin (STZ-lep) at a dosage (150 g/kg/day) calculated to
restore plasma leptin levels to nondiabetic control values. Leptin was ob-
tained from Dr. A.F. Parlow (National Hormone and Peptide Program) and
diluted in PBS (pH 7.9). A control nondiabetic group (veh-veh) received
sodium citrate rather than STZ, followed by implantation of a subcutaneous
osmotic minipump containing vehicle (PBS). Finally, to control for the effect
of leptin to reduce food intake in rats with STZ-induced diabetes (8), an
additional group of diabetic animals receiving vehicle were pair fed (STZ-veh-
PF) to match the intake of STZ-lep–treated animals as previously described
(6). Food intake, body weight, and blood glucose levels were measured daily
during the mid-light cycle for 18 days.
The experimental paradigm described above was subsequently repeated in
separate groups of animals, with the exception that an indwelling catheter was
inserted into the left carotid artery as previously described (16), before STZ
administration to permit blood sampling from conscious, unstressed rats for
determination of plasma glucagon, catecholamine, and corticosterone levels.
Body composition and indirect calorimetry. Determinations of body lean
and fat mass were made on a separate group of animals using quantitative
magnetic resonance 11 days after STZ administration (EchoMRI-700TM; Echo
Medical Systems, Houston, TX). Locomotor activity was assessed by the
infrared beam breaks using an Opto-Varimetrix-3 sensor system (Columbus
Instruments, Columbus, OH). Indirect calorimetry was performed on this
same group of animals using a computer-controlled calorimetry system
(Oxymax; Columbus Instruments) in habituated animals as previously de-
scribed (17).
Measurement of insulin sensitivity. To determine the effect of leptin
replacement on STZ-induced insulin resistance, animals from each group were
subjected to an insulin tolerance test (ITT) on day 16 after STZ injection.
Brieﬂy, after a 3-h fast mid-light cycle, animals received an injection of insulin
(2 units/kg i.p., Humulin R; Lilly), and glucose levels were determined on
tail-vein blood samples using a hand-held glucometer (Accu-Chek; Roche) at
time 0 and at 30-min intervals over 120 min.
Blood and urine collection and assay. Urinary glucose was measured using
a GM9D glucose direct analyzer (Analox Instruments, London, U.K.) on urine
samples obtained from animals 14 days after STZ administration. Tail-vein
blood samples were collected in chilled EDTA-treated tubes for measurement
of plasma insulin and leptin on days 0, 1, 2, 3, 4, 7, and 16, and nonesteriﬁed
free fatty acids (NEFAs) on day 16. On day 16, arterial blood for catechol-
amine, corticosterone, and glucagon assays was collected from conscious,
freely moving animals and placed into tubes containing EGTA/glutathione,
EDTA, and benzamidine (10 l of 1 mol/l)/heparin (1 unit), respectively. Whole
blood was centrifuged at 1,500 rpm for 20 min, plasma was removed,
aliquoted, and stored at 20°C for subsequent analysis. Plasma immunoreac-
tive insulin and leptin levels were determined by ELISA (Crystal Chem). Free
fatty acids were measured using a colorimetric assay kit that relies on fatty
acid as substrate for enzymatic acylation of CoA (Wako Chemicals). Catechol-
amine levels were measured in duplicate using a sensitive and speciﬁc radioen-
zymatic assay (18). Glucagon was assayed with a glucagon radioimmunoassay kit
(Linco Research), and plasma corticosterone levels were measured using enzyme
immunosorbent assay (Diagnostics Systems Laboratories).
Tissue processing and biochemical analysis. To measure tissue insulin
sensitivity, 18 days after STZ injection, animals were fasted for a 4-h mid-light
cycle, injected with either vehicle or insulin (2 units/kg i.p.), and killed 15 min
later. Liver, skeletal muscle (tibialis anterior), and white adipose tissue (WAT)
(epididymal depot) were excised and snap frozen for subsequent analysis.
Tissues were homogenized in T-Per lysis buffer (10 l/mg tissue) (Pierce)
supplemented with protease and phosphatase inhibitor cocktails (Roche).
Homogenates were centrifuged, pellets were discarded, supernatants were
retained for determination of protein content using a Micro BCA protein assay
kit (Pierce), and equal amounts of protein were used for each condition in
each assay. Insulin-induced activation of PI3K was assessed in tissues by
measuring serine phosphorylation of Akt (residue 473) using an ELISA assay
(Invitrogen). Liver tissue triglyceride content was determined using quantita-
tive magnetic resonance with the Echo 3-in-1 MRI machine (Echo Medical
Systems).
RT-PCR. Total RNA was extracted from liver and pancreas using TRIzol B
(MRC), quantiﬁed by spectrophotometry (NanoDrop 1000; Thermo Scientiﬁc,
IL), and reverse-transcribed (1 g) with avian myeloblastosis virus reverse
transcriptase (Promega). RT-PCR was then performed on an ABI Prism 7900
HT (Applied Biosystems) using SYBR Green Master Mix (Applied Biosys-
tems). PCR data were analyzed using the Sequence Detection System software
(SDS version 2.2; Applied Biosystems). Expression levels of each gene were
normalized to a housekeeping gene (18S RNA) and expressed as a percentage
of veh-veh controls. Nontemplate controls were incorporated into each PCR
run.
Statistical analysis. All results are expressed as means  SEM. Statistical
analyses were performed using Statistica (version 7.1; StatSoft). A one-way
analysis of variance with a least signiﬁcant difference post hoc test was used
to compare mean values among multiple groups, and a two-sample unpaired
Student t test was used for two-group comparisons. In all instances, P  0.05
was considered signiﬁcant.
RESULTS
Effect of physiologic leptin replacement on glucose
and energy homeostasis during STZ-induced diabe-
tes. As expected (8), plasma insulin levels were dramati-
cally reduced by day 2 in all animals that received STZ
relative to nondiabetic controls, and they remained very
low throughout the duration of the study (Fig. 1A). The
effect of STZ on plasma leptin levels closely paralleled its
effect on plasma insulin levels, with marked reductions
observed by day 2 in diabetic animals receiving subcuta-
neous vehicle (Fig. 1B). By design, STZ-induced diabetic
animals that received continuous subcutaneous leptin
exhibited plasma leptin levels comparable with nondia-
betic control values throughout the study (Fig. 1B).
As expected, the reduction of plasma insulin levels in
animals made diabetic by STZ caused marked hyperglyce-
mia (Fig. 1C). Although marked hyperglycemia was also
observed in STZ-treated animals that received subcutane-
ous leptin, the magnitude of this effect was modestly
reduced compared with that in diabetic animals receiving
vehicle (P  0.05), indicating that leptin deﬁciency exac-
erbates (but is not a major cause of) hyperglycemia in rats
with uDM. This modest glucose-lowering effect of leptin
replacement, however, cannot be explained by reduced
J.P. GERMAN AND ASSOCIATES
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STZ-induced diabetic animals that were pair fed to the
intake of STZ-induced diabetic rats receiving subcutane-
ous leptin. By comparison, blood glucose levels remained
within the normal range in nondiabetic controls.
In diabetic animals receiving subcutaneous vehicle,
food intake was increased by day 6 after STZ administra-
tion and remained elevated compared with nondiabetic
controls (Fig. 1D). In comparison, consistent with previ-
ous reports (8), diabetic hyperphagia was prevented by
maintaining plasma leptin levels in the physiologic range,
such that food intake was comparable with that of nondi-
abetic controls (8) (Fig. 1D).
Although body weight gradually increased in nondia-
betic rats during the study, it decreased immediately after
diabetes onset in STZ-treated rats receiving vehicle and
remained signiﬁcantly below baseline values despite their
pronounced hyperphagia (Fig. 2A). STZ-induced diabetic
animals that were pair fed to the intake of leptin-treated
diabetic rats exhibited even greater weight loss than
diabetic rats fed ad libitum, owing to their reduced food
intake. Interestingly, STZ-induced diabetic rats that re-
ceived subcutaneous leptin lost signiﬁcantly less weight
than STZ-veh-PF animals, maintaining weight comparable
with diabetic rats fed ad libitum, despite consuming less
food.
To explore the basis for these body weight changes, we
subjected a separate cohort of animals to the same proto-
col and measured body composition analysis and indirect
calorimetry 11 days after STZ administration. We found
that leptin treatment caused a greater loss of body fat
mass in STZ-induced diabetic animals than was observed
in those receiving vehicle (Fig. 2B), but also spared lean
body mass relative to STZ-veh-PF animals (Fig. 2C). More-
over, using indirect calorimetry, we found that VO2 was
markedly increased in vehicle-treated STZ-induced dia-
betic animals relative to nondiabetic controls, regardless
of whether they were fed ad libitum or pair fed and that
this hypermetabolic effect was attenuated by physiologic
leptin replacement (Fig. 2D). However, the increased
metabolic rate in STZ-induced diabetic animals could not
be attributed to changes in ambulatory activity (number of
beam breaks: 2,953  243 for veh-veh vs. 1,562  87 for
STZ-veh vs. 2,215  163 for STZ-lep vs. 2,927  207 for
STZ-veh-PF). Respiratory quotient and metabolic heat
production are not reported because the assumptions
involved in using the respiratory quotient to estimate heat
production are not met in abnormal metabolic states,
including those characterized by a shift to ketone utiliza-
tion as a metabolic substrate or during rapid depletion of
protein and fat stores (19,20). Nonetheless, these data
collectively suggest that increased energy expenditure in
STZ-veh-PF relative to STZ-lep-treated animals probably
contributes to their excessive weight loss and depletion of
lean mass, despite consuming equal amounts of food.
Effect of physiologic leptin replacement on insulin
sensitivity in rats with STZ-induced diabetes. Consis-
tent with a previous report that insulin resistance is
progressive over time in rats with STZ-induced diabetes
(13), we conﬁrmed that the glucose-lowering effect of
insulin was markedly diminished on day 16 compared with
day 7 after STZ administration (P  0.05) (Fig. 3A). To
determine whether reduced plasma leptin levels contrib-
ute to this progressive insulin resistance, animals that
received either vehicle or a physiologic replacement dose
of leptin were subjected to an ITT 16 days after induction
of uDM with STZ. Relative to STZ-treated animals receiv-
ing vehicle, the ability of insulin to reduce blood glucose
was dramatically enhanced in those that received leptin
(P  0.05) (Fig. 3B). To account for differences in the level
of hyperglycemia at the onset of the ITT, insulin-induced
changes of blood glucose were also analyzed as a percent-
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FIG. 1. Physiologic leptin replacement attenuates diabetic hyperglycemia and diabetic hyperphagia in STZ-treated rats. Plasma insulin (A),
plasma leptin (B), blood glucose (C), and mean daily food intake (D) in STZ-induced diabetic animals receiving either vehicle and fed ad libitum
() or pair fed (), a physiologic replacement dose of leptin () or nondiabetic controls (Œ). *P < 0.05 vs. STZ-lep; #P < 0.05 vs. STZ-veh-PF.
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glucose levels were analyzed as absolute values or as
percent basal, physiologic leptin replacement in STZ-
induced diabetes markedly increased insulin sensitivity via
a mechanism that could not be attributed to changes in
food intake, since it was not observed in STZ-veh-PF
animals (Fig. 3B–D).
Effects of STZ-induced diabetes with or without
physiologic leptin replacement on insulin signal
transduction. To further characterize the impact of phys-
iologic leptin replacement on insulin action in uDM, we
examined insulin-induced activation of the IRS-PI3K-Akt
signal transduction pathway in liver, muscle, and WAT.
After intraperitoneal saline, there were no differences in
levels of pS473-Akt in any tissue among treatment groups,
but, as expected, systemic insulin injection signiﬁcantly
increased levels of pS473-Akt in liver, muscle, and WAT in
all groups compared with saline (P  0.05) (Fig. 3). In liver
tissue, the ability of insulin to increase levels of pS473-Akt
was reduced in STZ-treated animals receiving vehicle
compared with nondiabetic controls, and this effect was
prevented by physiologic leptin replacement (Fig. 4A).
Furthermore, because insulin-stimulated production of
pS473-Akt was also reduced in STZ-veh-PF livers, the
effect of leptin to normalize this response cannot be
explained by reduced food intake. In contrast, insulin-
induced activation of pS473-Akt in skeletal muscle was not
affected by either STZ-induced diabetes or by leptin ad-
ministration (Fig. 4B). Finally, although insulin signiﬁ-
cantly increased pS473-Akt in WAT of animals in each
group relative to saline-injected controls, the response to
insulin was signiﬁcantly attenuated in all STZ-induced
diabetic animals relative to that in nondiabetic controls
(Fig. 4C).
Potential mechanisms whereby leptin deﬁciency
causes insulin resistance in STZ-induced diabetes.
Uncontrolled diabetes is associated with increased circu-
lating levels of both glucagon and corticosterone, and
these responses are implicated in diabetes manifestations
including insulin resistance, hyperglycemia, and hyperpha-
gia (21–23). Based on recent evidence that adenovirally
induced hyperleptinemia ameliorates hyperglycemia via
normalization of elevated plasma glucagon levels (14), we
determined whether maintaining physiologic leptin levels
also is sufﬁcient to prevent diabetes-induced increases of
plasma glucagon and broadened the hypothesis to include
other counterregulatory hormones. Consistent with the
aforementioned ﬁndings (14), plasma glucagon levels were
elevated in STZ-treated animals receiving vehicle relative
to that in nondiabetic controls, and this elevation was
prevented by physiologic leptin replacement (Fig. 5A).
Thus, leptin deﬁciency appears to be required for the effect
of uDM to raise glucagon levels. Similarly, plasma cortico-
sterone levels were increased in STZ-treated rats, and this
effect was also attenuated by leptin replacement (Fig. 5B).
In contrast, plasma norepinephrine and epinephrine levels
were similar across treatment groups (Fig. 5C and D).
Normalization of both plasma glucagon and corticosterone
levels may therefore contribute to improved hepatic insu-
lin sensitivity and modest reduction of plasma glucose
induced by leptin replacement, but catecholamines are
unlikely to be involved.
To investigate whether changes in plasma or tissue lipid
accumulation might contribute to the effect of leptin on
insulin sensitivity, we measured both plasma NEFA levels
and triglyceride content in liver. We found no differences
in either plasma NEFA levels (day 16) or liver triglyceride
content in STZ-veh–treated animals compared with nondi-
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libitum or pair fed, but these levels were both reduced in
diabetic animals that received leptin (Fig. 6A and B).
To investigate the role of leptin deﬁciency in the effect
of uDM to increase hepatic glucose production and he-
patic insulin resistance (24), we used real-time PCR to
measure hepatic expression of mRNA encoding G6Pase
and Pepck in the absence of insulin injection. As expected,
levels of both mRNA species were elevated in diabetic
animals that received vehicle relative to nondiabetic con-
trols (Fig. 6C and D). In contrast, hepatic expression of
both G6Pase and Pepck genes was comparable between
diabetic animals receiving leptin and nondiabetic controls
and was signiﬁcantly below vehicle-treated diabetic ani-
mals. This effect is not attributable to reduced food intake,
since pair feeding was without effect (Fig. 6C and D). A
similar pattern of hepatic expression was seen for mRNA
encoding peroxisome proliferator–activated receptor-–
coactivator-1 (PGC-1), a transcriptional coregulator im-
plicated in the activation of both G6Pase and Pepck. Thus,
leptin deﬁciency is required for increased hepatic expres-
sion of gluconeogenic genes in uDM. By comparison,
Igfbp2, a recently reported hepatic gene implicated in the
action of leptin to suppress hepatic glucose production
(15), was increased 	20-fold in STZ-induced diabetic rats
relative to nondiabetic controls, and this diabetes-induced
upregulation was not affected by leptin treatment (Fig. 6F).
DISCUSSION
Growing evidence suggests that either impaired or deﬁ-
cient leptin signaling results in the development of insulin
resistance and impaired glucose metabolism (1,4–6,25).
Here, we report that leptin deﬁciency also contributes to
the development of progressive insulin resistance and
associated neuroendocrine derangements in uDM. We
found that systemic administration of exogenous leptin at
a dose that maintains normal physiologic plasma leptin
levels prevented the development of severe, progressive
insulin resistance in rats with uDM and that this effect
could not be explained by leptin-induced changes in food
intake or body weight. Moreover, the mechanism underly-
ing this effect appears to preferentially involve the liver, as
physiologic leptin replacement in uDM reduced hepatic
triglyceride content and gluconeogenic gene expression
and also restored insulin signal transduction to normal in
liver, but not in skeletal muscle or WAT. In addition,
physiologic leptin replacement in uDM reduced body fat
while sparing lean mass, attenuated the increased energy
expenditure that accompanies uDM (26), and normalized
elevated levels of plasma glucagon and corticosterone.
Taken together, these ﬁndings implicate leptin deﬁciency
as a cause of wide-ranging metabolic and neuroendocrine
derangements associated with uDM.
Although insulin resistance is a well-documented com-
plication of uDM (10–12,27), few studies have sought to
identify the underlying mechanism. Some investigators
have postulated a role for hyperglycemia, based on a
model in which “glucose toxicity” impairs insulin signal
transduction in peripheral tissues (28,29). Consistent with
this, insulin resistance in individuals with type 1 diabetes
is attenuated when glycemic control is improved (30,31),
whereas uncontrolled hyperglycemia induces insulin resis-
tance in these individuals (32,33). Our ﬁnding that physi-
ologic leptin replacement prevented uDM-induced insulin
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hyperglycemia, however, suggests that in this study, hy-
perglycemia per se is unlikely to play a major role.
Although reduced food intake might also be expected to
contribute to the insulin-sensitizing effects of leptin, this
possibility is inconsistent with our ﬁnding that diabetic
animals pair fed to the intake of those receiving leptin
failed to exhibit an improvement of insulin sensitivity.
In light of the potent insulin-sensitizing effect of leptin
replacement in rats with uDM, it is reasonable to ask why
the effect on hyperglycemia was so modest. Presumably
this reﬂects the severe insulin deﬁciency characteristic of
this model, such that improved insulin sensitivity has little
impact on ambient glucose levels in the absence of insulin
therapy. This observation also highlights an important
distinction between the effect of physiologic leptin re-
placement we observed in the current work, and recent
work examining the effect of pharmacologic hyperleptine-
mia in uDM (5,14). In the latter, induction of very high
circulating leptin levels in rodents with uDM resulted in
full normalization of hyperglycemia, whereas this clearly
was not the case in our study. Thus, normalization of
hyperglycemia in uDM cannot be achieved simply by
physiologic replacement of endogenous leptin, but appar-
ently requires pharmacologic levels of leptin.
Complementing our ﬁnding that physiologic leptin re-
placement enhances insulin-mediated glucose lowering in
STZ-induced diabetic animals, we found that this interven-
tion also restored insulin signaling in liver, but not in
skeletal muscle or adipose tissue, as measured by insulin-
induction of pAkt. The mechanisms underlying this im-
provement in hepatic insulin signaling remain uncertain
but could involve reductions of body fat mass and/or liver
triglyceride content. Alternatively, we recently reported
that leptin action in the hypothalamic arcuate nucleus
improves hepatic insulin action via a mechanism involving
the hepatic vagus nerve (6). Thus, additional studies are
warranted to determine whether this autonomic mecha-
nism might also contribute to the improved insulin sensi-
tivity after physiologic leptin replacement in uDM.
Studies have shown that uDM is associated with in-
creased plasma glucagon levels and elevated hepatic ex-
pression of the gluconeogenic genes G6Pase and Pepck,
and these responses are implicated in the pathogenesis
of insulin resistance (34,35) and diabetic hyperglycemia
(21,22). Our ﬁnding that physiologic leptin replacement in
uDM dramatically improved insulin sensitivity and normal-
ized elevated levels of both plasma glucagon and hepatic
expression of these gluconeogenic genes is consistent
with this hypothesis. A recent study reported that hyper-
leptinemia induced by an adenoviral gene therapy ap-
proach ameliorated hyperglycemia in STZ-induced diabetes,
and this was hypothesized to occur via a suppression of
hyperglucagonemia and consequent reduction of hepatic
gluconeogenic gene expression (14). Previous studies, how-
ever, have not established the extent to which hyperglycemia
in uDM might be driven by increases of glucagon and
associated changes of glucose production. In this context, we
note that although plasma glucagon levels and hepatic ex-
pression of G6Pase and Pepck were normalized by physio-
logic leptin replacement in our study, hyperglycemia was
only slightly improved compared with that in diabetic ani-
mals that received vehicle. These data suggest that normal-
ization of plasma glucagon levels plays only a minor role in
leptin’s antidiabetic effects, although it remains possible that
hyperglucagonemia contributes to progressive insulin resis-
tance in uDM. Further, our ﬁndings identify for the ﬁrst time
a role for leptin deﬁciency in the effect of uDM to raise
circulating glucagon levels.
Hyperglucagonemia and the energy cost associated with
increased gluconeogenesis are implicated in the increased
metabolic rate in patients with poorly controlled type 1
diabetes, an effect that is reversed by insulin treatment
(26). Such a mechanism may also explain the marked
increase in energy expenditure in STZ-induced diabetic
rats relative to that of nondiabetic controls, as this cannot
be explained by changes in activity. Changes in food
intake are also unlikely to explain this metabolic response
to uDM, because metabolic rate was increased similarly in
STZ-veh and STZ-veh-PF groups. Although leptin has pre-
viously been demonstrated to increase energy expendi-
ture, at least in part via sympathetic activation of brown
adipose tissue (36), we found that the elevated metabolic
rate induced by uDM was attenuated by leptin replace-
ment. Although the mechanism underlying this leptin
effect awaits further study, suppression of elevated rates
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likely. To our knowledge, this is the ﬁrst demonstration of
an effect of leptin to lower metabolic rate, and it reinforces
the concept that the effect of leptin on metabolic regula-
tion is highly context dependent. These data also help
explain why leptin-treated diabetic animals lose weight in
amounts similar to those for animals receiving vehicle,
despite consuming much less food. Indeed, matching the
intake of STZ-veh animals by pair feeding to that of
leptin-replaced rats produced excessive weight loss. These
ﬁndings collectively suggest that leptin deﬁciency is a
major determinant of hypermetabolism induced by uDM.
It has been shown that uDM is also characterized by
increased glucocorticoid secretion and activation of the
hypothalamic-adrenal-pituitary (HPA) axis (37,38). Be-
cause glucocorticoids both inhibit peripheral glucose up-
take in muscle and adipose tissue and induce hepatic
expression of G6Pase and Pepck (39), HPA activation in
uDM probably contributes to insulin resistance in this
setting. Our ﬁnding that leptin replacement normalized
elevated plasma corticosterone levels in STZ-induced dia-
betic rats provides a plausible mechanism to explain the
observed improvement of insulin sensitivity but again
suggests that increased circulating glucocorticoid levels
are not a dominant cause of hyperglycemia in uDM. Also of
interest here is the implication that leptin deﬁciency
causes HPA activation in uDM, as has been suggested in
other conditions (40). In contrast, we observed no effect of
leptin replacement on plasma catecholamines.
Recently, it was reported that systemic administration
of leptin upregulates hepatic expression of Igfbp2 and
adenovirus-induced overexpression of IGFBP2 normalizes
blood glucose levels in insulin-resistant and uDM mice
(15). Our ﬁnding that hepatic expression of Igfpb2 was
increased 	20-fold in leptin-deﬁcient STZ-induced dia-
betic animals relative to that in nondiabetic controls,
however, suggests that increased hepatic expression of
this gene is unlikely to exert salutary effects in the setting
of uDM, an impression conﬁrmed by the absence of any
effect of leptin replacement on Igfpb2 mRNA levels. Thus,
hepatic Igfbp2 is unlikely to explain the effect of physio-
logic leptin replacement to improve insulin sensitivity in
uDM.
Several lines of evidence suggest that insulin resistance
occurs in patients with type 1 diabetes (10–12,27) and is
an independent risk factor for micro- and macrovascular
complications in these patients (41,42). However, thera-
peutic approaches currently available for treating insulin
resistance in type 1 diabetes are quite limited. Although
intensive insulin therapy in individuals with type 1 diabe-
tes improves insulin sensitivity and glycemic control, the
Diabetes Control and Complication Trial (DCCT) reported
that although intensive insulin therapy preserves pancre-
atic -cell function and improves retinopathy and neurop-
athy, these beneﬁts are offset by an increased frequency of
severe hypoglycemia and weight gain (43–45). In contrast,
treating type 1 diabetic subjects with lifestyle modiﬁcations,
such as diet (46) and exercise (47), or pharmaceutical
approaches using thiazolidinediones (48) or metformin (49),
yield improvements in insulin sensitivity in type 1 diabetic
subjects, but not glycemic control. Our current data raise the
possibility that a combination therapy approach using both
insulin and leptin treatment in type 1 diabetic patients may
reduce the amount of insulin required to achieve good
glycemic control and also limit weight gain (50).
In summary, we report that STZ-induced diabetes
causes a rapid and severe reduction of plasma leptin levels
that precedes the development of severe insulin resis-
tance. The latter effect was prevented by restoration of
plasma leptin to normal physiologic levels which also
reduced hepatic triglyceride content and restored normal
insulin signal transduction in the liver. Moreover, physio-
logic replacement of plasma leptin levels suppressed the
characteristic increase of plasma glucagon and corticoste-
rone levels and elevated hepatic expression of the glu-
coneogenic genes Pepck and G6Pase in uDM but only
modestly reduced the extent of hyperglycemia. These
ﬁndings also implicate leptin deﬁciency as a cause of
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tion of elevated plasma glucagon levels may contribute to
the antidiabetic effects of pharmacologic leptin therapy,
other factors must also be involved. We conclude that
leptin deﬁciency plays a major role in the progressive,
severe insulin resistance characteristic of uDM. This novel
ﬁnding also raises the therapeutic possibility that supple-
menting insulin treatment with leptin may be a useful
adjunct in the management of type 1 diabetes.
ACKNOWLEDGMENTS
This work was supported by National Institutes of Health
(grants DK-083042 and DK-052989 to M.W.S. and DK-
050154-13 to G.J.T.), by the Clinical Nutrition Research
Unit (grant DK-035816) at the University of Washington, by
research funding from AstraZeneca, and by a Scientist
Development Grant from the American Heart Association
(to G.J.M.).
No potential conﬂicts of interest relevant to this article
were reported.
Author contributions: J.P.G. and S.O.: research data,
contributed to discussion, and reviewed/edited manu-
script; B.E.W., J.P.T., D.A.S., G.J.T., and M.W.S.: contrib-
uted to discussion and reviewed/edited manuscript; K.O.
and K.J.K.: research data and reviewed/edited manuscript;
J.D.F. and M.E.M.: research data; G.J.M. research data,
contributed to discussion, wrote manuscript, and re-
viewed/edited manuscript.
Parts of this study were presented in poster form at the
70th annual meeting of the American Diabetes Associa-
tion, Orlando, Florida, 25–29 June 2010.
We acknowledge the excellent technical assistance pro-
vided by Alex Cubelo, Charles Davis, and Iaela David at
the University of Washington and Howard Chang from the
VA Puget Sound Health Care System for performing the
plasma glucagon and catecholamine measurements.
REFERENCES
1. Zhang Y, Proenca R, Maffei M, Barone M, Leopold L, Friedman JM.
Positional cloning of the mouse obese gene and its human homologue.
Nature 1994;372:425–432
2. Halaas JL, Boozer C, Blair-West J, Fidahusein N, Denton DA, Friedman JM.
Physiological response to long-term peripheral and central leptin infusion
in lean and obese mice. Proc Natl Acad Sci U S A 1997;94:8878–8883
3. Campﬁeld LA, Smith FJ, Guisez Y, Devos R, Burn P. Recombinant mouse
OB protein: evidence for a peripheral signal linking adiposity and central
neural networks. Science 1995;269:546–549
4. Schwartz MW, Baskin DG, Bukowski TR, Kuijper JL, Foster D, Lasser G,
Prunkard DE, Porte D Jr, Woods SC, Seeley RJ, Weigle DS. Speciﬁcity of
leptin action on elevated blood glucose levels and hypothalamic neuropep-
tide Y gene expression in ob/ob mice. Diabetes 1996;45:531–535
5. Chinookoswong N, Wang JL, Shi ZQ. Leptin restores euglycemia and
0.0
0.5
1.0
1.5
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
veh-veh
STZ-veh
STZ-lep
STZ-veh-PF
N
E
F
A
(
m
m
o
l
/
l
)
*
#
#
A B
C D
0
2
4
6
8
10
L
i
v
e
r
 
 
t
r
i
g
l
y
c
e
r
i
d
e
 
(
%
) *
# #
0
100
200
300
400
500
 
H
e
p
a
t
i
c
 
P
g
c
-
1
m
R
N
A
l
e
v
e
l
s
 
(
%
v
e
h
-
v
e
h
)
*
# *
#
*
0
1000
2000
3000
4000
5000
 
H
e
p
a
t
i
c
 
I
g
f
b
p
2
 
m
R
N
A
l
e
v
e
l
s
 
(
%
v
e
h
-
v
e
h
)
*
*
*
E F
0
100
200
300
 
 
 
 
H
e
p
a
t
i
c
 
P
e
p
c
k
m
R
N
A
l
e
v
e
l
s
 
(
%
v
e
h
-
v
e
h
) *
# *
#
0
50
100
150
200
250
H
e
p
a
t
i
c
 
G
6
P
a
s
e
 
m
R
N
A
l
e
v
e
l
s
 
(
%
v
e
h
-
v
e
h
)
*
# *
#
FIG. 6. Physiologic leptin replacement reduces plasma and hepatic lipid content and gluconeogenic gene expression. Plasma NEFAs obtained from
tail-vein samples (A), hepatic triglyceride content (B) and expression of G6Pase (C), Pepck (D), Pgc-1 (E), and Igfbp2 (F) using real-time PCR
in nondiabetic controls (veh-veh) or in STZ-induced diabetic animals receiving either vehicle and fed ad libitum (STZ-veh) or pair fed
(STZ-veh-PF) or a physiologic replacement dose of leptin (STZ-lep). *P < 0.05 vs. veh-veh; #P < 0.05 vs. STZ-lep.
J.P. GERMAN AND ASSOCIATES
diabetes.diabetesjournals.org DIABETES, VOL. 59, JULY 2010 1633normalizes glucose turnover in insulin-deﬁcient diabetes in the rat. Diabe-
tes 1999;48:1487–1492
6. Morton GJ, Gelling RW, Niswender KD, Morrison CD, Rhodes CJ, Schwartz
MW. Leptin regulates insulin sensitivity via phosphatidylinositol-3-OH
kinase signaling in mediobasal hypothalamic neurons. Cell Metab 2005;2:
411–420
7. Havel PJ, Uriu-Hare JY, Liu T, Stanhope KL, Stern JS, Keen CL, Ahre ´n B.
Marked and rapid decreases of circulating leptin in streptozotocin diabetic
rats: reversal by insulin. Am J Physiol 1998;274:R1482–1491
8. Sindelar DK, Havel PJ, Seeley RJ, Wilkinson CW, Woods SC, Schwartz MW.
Low plasma leptin levels contribute to diabetic hyperphagia in rats.
Diabetes 1999;48:1275–1280
9. Booth DA. Some characteristics of feeding during streptoxotocin-induced
diabetes in the rat. J Comp Physiol Psychol 1972;80:238–249
10. DeFronzo RA, Simonson D, Ferrannini E. Hepatic and peripheral insulin
resistance: a common feature of type 2 (non-insulin-dependent) and type 1
(insulin-dependent) diabetes mellitus. Diabetologia 1982;23:313–319
11. DeFronzo RA, Hendler R, Simonson D. Insulin resistance is a prominent
feature of insulin-dependent diabetes. Diabetes 1982;31:795–801
12. Yki-Ja ¨rvinen H, Koivisto VA. Natural course of insulin resistance in type I
diabetes. N Engl J Med 1986;315:224–230
13. Gelling RW, Morton GJ, Morrison CD, Niswender KD, Myers MG Jr,
Rhodes CJ, Schwartz MW. Insulin action in the brain contributes to
glucose lowering during insulin treatment of diabetes. Cell Metab 2006;3:
67–73
14. Yu X, Park BH, Wang MY, Wang ZV, Unger RH. Making insulin-deﬁcient
type 1 diabetic rodents thrive without insulin. Proc Natl Acad SciUSA
2008;105:14070–14075
15. Hedbacker K, Birsoy K, Wysocki RW, Asilmaz E, Ahima RS, Farooqi IS,
Friedman JM. Antidiabetic effects of IGFBP2, a leptin-regulated gene. Cell
Metab 2010;11:11–22
16. German J, Kim F, Schwartz GJ, Havel PJ, Rhodes CJ, Schwartz MW,
Morton GJ. Hypothalamic leptin signaling regulates hepatic insulin sensi-
tivity via a neurocircuit involving the vagus nerve. Endocrinology 2009;
150:4502–4511
17. Gelling RW, Yan W, Al-Noori S, Pardini A, Morton GJ, Ogimoto K, Schwartz
MW, Dempsey PJ. Deﬁciency of TNF converting enzyme (TACE/
ADAM17) causes a lean, hypermetabolic phenotype in mice. Endocrinol-
ogy 2008;149:6053–6064
18. Evans MI, Halter JB, Porte D Jr. Comparison of double- and single-isotope
enzymatic derivative methods for measuring catecholamines in human
plasma .Clin Chem 1978;24:567–570
19. Ferrannini E. The theoretical bases of indirect calorimetry: a review.
Metabolism 1988;37:287–301
20. Schutz Y. On problems of calculating energy expenditure and substrate
utilization from respiratory exchange data. Z Ernahrungswiss 1997;36:255–
262
21. Mu ¨ller WA, Faloona GR, Unger RH. The effect of experimental insulin
deﬁciency on glucagon secretion. J Clin Invest 1971;50:1992–1999
22. Dobbs R, Sakurai H, Sasaki H, Faloona G, Valverde I, Baetens D, Orci L,
Unger R. Glucagon: role in the hyperglycemia of diabetes mellitus. Science
1975;187:544–547
23. Scribner KA, Walker CD, Cascio CS, Dallman MF. Chronic streptozotocin
diabetes in rats facilitates the acute stress response without altering
pituitary or adrenal responsiveness to secretagogues. Endocrinology 1991;
129:99–108
24. Wahren J, Ekberg K. Splanchnic regulation of glucose production. Annu
Rev Nutr 2007;27:329–345
25. Coppari R, Ichinose M, Lee CE, Pullen AE, Kenny CD, McGovern RA, Tang
V, Liu SM, Ludwig T, Chua SC Jr, Lowell BB, Elmquist JK. The hypotha-
lamic arcuate nucleus: a key site for mediating leptin’s effects on glucose
homeostasis and locomotor activity. Cell Metab 2005;1:63–72
26. Nair KS, Halliday D, Garrow JS. Increased energy expenditure in poorly
controlled type 1 (insulin-dependent) diabetic patients. Diabetologia 1984;
27:13–16
27. Perseghin G, Lattuada G, Danna M, Sereni LP, Mafﬁ P, De Cobelli F,
Battezzati A, Secchi A, Del Maschio A, Luzi L. Insulin resistance, intramyo-
cellular lipid content, and plasma adiponectin in patients with type 1
diabetes. Am J Physiol Endocrinol Metab 2003;285:E1174–1181
28. Unger RH, Grundy S. Hyperglycaemia as an inducer as well as a conse-
quence of impaired islet cell function and insulin resistance: implications
for the management of diabetes. Diabetologia 1985;28:119–121
29. Poitout V, Robertson RP. Glucolipotoxicity: fuel excess and beta-cell
dysfunction. Endocr Rev 2008;29:351–366
30. Lager I, Lonnroth P, von Schenck H, Smith U. Reversal of insulin resistance
in type I diabetes after treatment with continuous subcutaneous insulin
infusion. Br Med J (Clin Res Ed) 1983;287:1661–1664
31. Yki-Ja ¨rvinen H, Koivisto VA. Continuous subcutaneous insulin infusion
therapy decreases insulin resistance in type 1 diabetes. J Clin Endocrinol
Metab 1984;58:659–666
32. Vuorinen-Markkola H, Koivisto VA, Yki-Jarvinen H. Mechanisms of hyper-
glycemia-induced insulin resistance in whole body and skeletal muscle of
type I diabetic patients. Diabetes 1992;41:571–580
33. Yki-Ja ¨rvinen H, Helve E, Koivisto VA. Hyperglycemia decreases glucose
uptake in type I diabetes. Diabetes 1987;36:892–896
34. Trinh KY, O’Doherty RM, Anderson P, Lange AJ, Newgard CB. Perturbation
of fuel homeostasis caused by overexpression of the glucose-6-phospha-
tase catalytic subunit in liver of normal rats. J Biol Chem 1998;273:31615–
31620
35. Sun Y, Liu S, Ferguson S, Wang L, Klepcyk P, Yun JS, Friedman JE.
Phosphoenolpyruvate carboxykinase overexpression selectively attenu-
ates insulin signaling and hepatic insulin sensitivity in transgenic mice.
J Biol Chem 2002;277:23301–23307
36. Scarpace PJ, Matheny M, Pollock BH, Tu ¨mer N. Leptin increases uncou-
pling protein expression and energy expenditure. Am J Physiol 1997;273:
E226–230
37. Strack AM, Sebastian RJ, Schwartz MW, Dallman MF. Glucocorticoids and
insulin: reciprocal signals for energy balance. Am J Physiol 1995;268:R142–
R149
38. Schwartz MW, Strack AM, Dallman MF. Evidence that elevated plasma
corticosterone levels are the cause of reduced hypothalamic corticotro-
phin-releasing hormone gene expression in diabetes. Regul Pept 1997;72:
105–112
39. Exton JH. Regulation of gluconeogenesis by glucocorticoids. Monogr
Endocrinol 1979;12:535–546
40. Ahima RS, Prabakaran D, Mantzoros C, Qu D, Lowell B, Maratos-Flier E,
Flier JS. Role of leptin in the neuroendocrince response to fasting. Nature
1996;382:250–252
41. Chaturvedi N, Sjoelie AK, Porta M, Aldington SJ, Fuller JH, Songini M,
Kohner EM, EURODIAB Prospective Complications Study. Markers of
insulin resistance are strong risk factors for retinopathy incidence in type
1 diabetes. Diabetes Care 2001;24:284–289
42. Soedamah-Muthu SS, Chaturvedi N, Toeller M, Ferriss B, Reboldi P, Michel
G, Manes C, Fuller JH. Risk factors for coronary heart disease in type 1
diabetic patients in Europe: the EURODIAB Prospective Complications
Study. Diabetes Care 2004;27:530–537
43. The DCCT Research Group. Weight gain associated with intensive therapy
in the Diabetes Control and Complications Trial. Diabetes Care 1988;11:
567–573
44. The Diabetes Control and Complications Trial Research Group. The effect
of intensive treatment of diabetes on the development and progression of
long-term complications in insulin-dependent diabetes mellitus. N Engl
J Med 1993;329:977–986
45. The Diabetes Control and Complications Trial Research Group. Hypogly-
cemia in the Diabetes Control and Complications Trial. Diabetes 1997;46:
271–286
46. Rosenfalck AM, Almdal T, Viggers L, Madsbad S, Hilsted J. A low-fat diet
improves peripheral insulin sensitivity in patients with type 1 diabetes.
Diabet Med 2006;23:384–392
47. Yki-Ja ¨rvinen H, DeFronzo RA, Koivisto VA. Normalization of insulin
sensitivity in type I diabetic subjects by physical training during insulin
pump therapy. Diabetes Care 1984;7:520–527
48. Strowig SM, Raskin P. The effect of rosiglitazone on overweight subjects
with type 1 diabetes. Diabetes Care 2005;28:1562–1567
49. Pang TT, Narendran P. Addressing insulin resistance in type 1 diabetes.
Diabet Med 2008;25:1015–1024
50. Miyanaga F, Ogawa Y, Ebihara K, Hidaka S, Tanaka T, Hayashi S, Masuzaki
H, Nakao K. Leptin as an adjunct of insulin therapy in insulin-deﬁcient
diabetes. Diabetologia 2003;46:1329–1337
LEPTIN DEFICIENCY AND INSULIN RESISTANCE
1634 DIABETES, VOL. 59, JULY 2010 diabetes.diabetesjournals.org